The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
Open accessAbstract
CONTEXT: Associations of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified. OBJECTIVE: To assess major lipids and apolipoproteins in vascular risk. DESIGN, SETTING, AND PARTICIPANTS: Individual records were supplied on 302,430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America. During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes. MAIN OUTCOME MEASURES: Hazard ratios (HRs), adjusted for several conventional factors, were calculated for 1-SD higher values: 0.52 log(e) triglyceride, 15 mg/dL high-density lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis. RESULTS: The rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C. Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C. Hazard ratios were at least as strong in participants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C. CONCLUSION: Lipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“fasting and nonfasting TG levels were associated with increased risk of coronary heart disease”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the association was attenuated after adjustment for HDL-C”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“was nonsignificant after adjustment for non-HDL-C”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The hazard ratio for coronary heart disease with triglycerides was 1.37 (95% CI, 1.31-1.42)after adjustment for nonlipid factors, but was reduced to 0.99 (95% CI, 0.94 -1.05) after adjustment for HDL cholesterol and non-HDL cholesterol (9).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Risk associations are similar in nonfasting study populations than in those who did fast [72,74].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“TGs were not associated with stroke after adjustment for lipids”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [72]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A serum triglyceride level of 150 mg/dl (1.7 mmol/liter) usually falls below the 75th percentile in various populations, although there have been well-established differences identified between racial and ethnic groups (6 -9).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis.”
In the citing paper
“Over the past three decades, epidemiologic and genetic evidence has accumulated to support the concept that elevated levels of plasma TG, TRL, and TRL remnants are causally related to an increased risk of ASCVD-related events—myocardial infarction (MI), stroke, and aortic valve stenosis—and all-cause mortality.1,2,17,19,20,24–28”
In the citing paper
“Recent data from a meta-analysis by the Emerging Risk Factor Collaboration 42 indicate that apo B does not provide any benefit beyond non-HDL-C or traditional lipid ratios.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [42]
In the citing paper
“Alternatively apo B and the apo B/apo A1 ratio can be used, which have been found to be at least as good risk markers compared with traditional lipid parameters.42”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [42]
In the citing paper
“Recently, non-HDL-C has turned out to be a good surrogate marker of TG and remnants.42”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [42]
In the citing paper
“After adjustment for HDL cholesterol, there is no significant association between triglycerides and CVD.52”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [52]
In the citing paper
“Very high levels of HDL-C have consistently not been found to be associated with atheroprotection. 90”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [90]
In the citing paper
“Very high levels of HDL-C have consistently not been found to be associated with atheroprotection.90”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [90]
In the citing paper
“Recent data from a meta-analysis 83,90 indicate that apoB does not provide any benefit beyond non-HDL-C or traditional lipid ratios.101”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [90]
In the citing paper
“The relationship between HDL-C and cardiovascular risk is not linear; for instance, no further improvement in prognosis is seen with HDL-C levels above ~60 mg/dl (1.5 mmol/l) (Fig. 1) [3].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [3]
In the citing paper
“With adjustment for age and sex, triglycerides showed a strong, stepwise association with both CVD and ischemic stroke; however, after adjustment for standard risk factors and for HDL-C and non-HDL-C, the associations for both CVD and stroke were no longer significant.”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [17]
In the citing paper
“Such an effect modification could obscure a modest but significant effect, as demonstrated recently.17”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [17]
In the citing paper
“With adjustment for age and sex, triglycerides showed a strong, stepwise association with both CVD and ischemic stroke; however, after adjustment for standard risk factors and for HDL-C and non-HDL-C, the associations for both CVD and stroke were no longer significant.”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,770
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Kumar, M. V. J., & Chippada, A. R. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update
Pearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., Franklin, B. A., Goldstein, L. B., Greenland, P., Grundy, S. M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000020190.45892.75 · Cited by 1,837
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227
McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 844
Nonfasting triglycerides and risk of ischemic stroke in the general population
Freiberg, J. J. (2008) · JAMA · doi:10.1001/jama.2008.621 · Cited by 542
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 526
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Briel, M., Ferreira-Gonzalez, I., You, J. J., Karanicolas, P. J., Akl, E. A., Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., et al. (2009) · BMJ · doi:10.1136/bmj.b92 · Cited by 491
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Frikke-Schmidt, R. (2008) · JAMA · doi:10.1001/jama.299.21.2524 · Cited by 464
Drug treatment of lipid disorders.
Broeders, N., Knoop, C., & Abramowicz, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412617 · Cited by 385
Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups
Tirschwell, D., Smith, N. L., Heckbert, S. R., Lemaître, R. N., Longstreth, W. T., Jr., & Psaty, B. M. (2004) · Neurology · doi:10.1212/01.wnl.0000144282.42222.da · Cited by 343
The Emerging Risk Factors Collaboration (2007) · European Journal of Epidemiology · doi:10.1007/s10654-007-9165-7 · Cited by 192
Self-citationBissell, M. G. (2008) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(08)70739-4 · Cited by 137
Parish, S., Peto, R., Palmer, A. J., Clarke, R. T., Lewington, S., Offer, A. R., Whitlock, G., Clark, S., Youngman, L. D., Sleight, P., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp221 · Cited by 121
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M. J., & Eriksson, M. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.02.014 · Cited by 111
Wood, A., White, I. R., Thompson, S. G., Lewington, S., & Danesh, J. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl233 · Cited by 97
Ballantyne, C. M., Davidson, M. H., McKenney, J. M., Keller, L. H., Bajorunas, D. R., & Karas, R. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.092 · Cited by 90
Fibrinogen Studies Collaboration (2009) · Statistics in Medicine · doi:10.1002/sim.3530 · Cited by 63
Wang, J., Ban, M. R., Kennedy, B. A., Anand, S. S., Yusuf, S., Huff, M. W., Pollex, R. L., & Hegele, R. A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1326 · Cited by 60
(2009) · Clinical Governance An International Journal · doi:10.1108/cgij.2009.24814dae.005 · Cited by 41
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Stockman, J. A. (2009) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(08)79001-8 · Cited by 28
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Howard, W. J. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79129-7 · Cited by 28
The Queen's University of Belfast
Stephens, A. V. (1963) · Aircraft Engineering and Aerospace Technology · doi:10.1108/eb033717 · Cited by 9
East Boston Neighborhood Health Center
&NA; (1996) · AJN American Journal of Nursing · doi:10.1097/00000446-199601001-00036 · Cited by 1
Cited by
Sorted by citations
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Metadata
- Authors
- The Emerging Risk Factors Collaboration*
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-11-11
- Volume
- 302
- Issue
- 18
- Pages
- 1993
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC3284229
- OpenAlex
- W2127427274
- Cited by
- 2,731
- References
- 41
- Citations by year
- 2026: 89 · 2025: 116 · 2024: 150 · 2023: 178 · 2022: 169 · 2021: 188 · 2020: 156 · 2019: 177 · 2018: 188 · 2017: 175 · 2016: 163 · 2015: 187 · 2014: 198 · 2013: 189 · 2012: 160
- FWCI
- 136.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation (RG/08/013/25942, RG/08/014, RG/07/008/23674, RG/08/014/24067)
- Economic and Social Research Council (ES/G007438/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Keywords
- apolipoproteins, vascular risk, coronary artery disease, myocardial infarction, ischemic stroke, hemorrhagic stroke, triglycerides, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, apolipoprotein A-I, apolipoprotein B, fasting state, lipid-lowering therapy, cardiovascular risk factors, prospective cohort, meta-analysis
- MeSH terms
- Apolipoproteins, Coronary Disease, Female, Humans, Lipids, Cholesterol, HDL, Male, Middle Aged, Regression Analysis, Risk Factors, Triglycerides, Vascular Diseases, Proportional Hazards Models, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
